FBB Neuraceq™, April 2020
The first of April 2020 FBB Neuraceq™.has been accepted by the compulsory national health insurance for reimbursement.
The product is a radiodiagnostic used to visualize the density of neuritic β-amyloid plaques in the brain of adult patients with cognitive impairment who are being examined for Alzheimer’s disease (AK) or other causes of cognitive impairment.
